2 Dividend Stocks to Buy Hand Over Fist in April
One factor that keeps some investors away from healthcare stocks is the sector's dearth of generous and reliable dividend payers. This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply.In this wide and deep sector, though, there are some notable exceptions. Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical companies Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).Amgen's involvement in the high-demand obesity drugs race has attracted attention recently, but the pharmaceutical sector star has been on the radar of clever investors for years. These days, it's a very healthy and thriving company with an enviable lineup of blockbuster drugs, and a strong pipeline. Continue reading
One factor that keeps some investors away from healthcare stocks is the sector's dearth of generous and reliable dividend payers. This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply.
In this wide and deep sector, though, there are some notable exceptions. Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical companies Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).
Amgen's involvement in the high-demand obesity drugs race has attracted attention recently, but the pharmaceutical sector star has been on the radar of clever investors for years. These days, it's a very healthy and thriving company with an enviable lineup of blockbuster drugs, and a strong pipeline.
